Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 6/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.35 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | CCR6 | P51684 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
| ▸ | CALCA | P06881 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17200937 | 0.94 | NR1D1 (0.35) | NR1D1MTNR1AMTNR1BNR1H3GSTO1 | |
| SCHEMBL18979341 | 0.94 | NR1D1 (0.35) | NR1D1MTNR1AMTNR1BNR1H3GSTO1 | |
| SCHEMBL26885902 | 0.93 | NR1D1 (0.33) | NR1D1MTNR1AMTNR1BNR1H3GSTO1 | |
| SCHEMBL6027858 | 0.91 | NR1D1 (0.34) | NR1D1MTNR1AMTNR1BNR1H3LCK | |
| SCHEMBL9356026 | 0.85 | NR1D1 (0.36) | NR1D1NR1H3GSTO1AKT1 | |
| SCHEMBL10367811 | 0.85 | NR1D1 (0.36) | NR1D1MTNR1AMTNR1BNR1H3GSTO1 | |
| SCHEMBL3477183 | 0.84 | NR1D1 (0.34) | NR1D1NR1H3AKT1 | |
| SCHEMBL5004491 | 0.81 | NR1D1 (0.34) | NR1D1NR1H3GSTO1ALDH1A1GLA | |
| SCHEMBL18674519 | 0.80 | NR1D1 (0.32) | NR1D1NR1H3 | |
| SCHEMBL5004256 | 0.78 | GABRA5 (0.37) | NR1D1NR1H3GSTO1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10365286-B2 | Chromophoric structures for lanthanide chelates | RADIOMETER TURKU OY (FI) | 2019-07-30 | — | — | US | disclosed |
| EP-3137573-B1 | NEW CHROMOPHORIC STRUCTURES FOR LANTHANIDE CHELATES FIELD OF THE INVENTION | RADIOMETER TURKU OY (FI) | 2018-08-01 | — | — | EP | disclosed |
| US-20170089913-A1 | NEW CHROMOPHORIC STRUCTURES FOR LANTHANIDE CHELATES | RADIOMETER TURKU OY (FI) | 2017-03-30 | — | — | US | disclosed |
| US-20170089913-A1 | NEW CHROMOPHORIC STRUCTURES FOR LANTHANIDE CHELATES | RADIOMETER TURKU OY (FI) | 2017-03-30 | — | — | US | disclosed |
| US-20080305049-A1 | Mri Contrast Agents for Diagnosis and Prognosis of Tumors | YEDA RESEARCH AND DEVELOPMENT CO. LTD. AT THE WEIZMANN INSTITUTE OF SCIENCE (IL) | 2008-12-11 | — | — | US | disclosed |
| EP-1848466-A2 | MRI CONTRAST AGENTS FOR DIAGNOSIS AND PROGNOSIS OF TUMORS | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006080022-A2 | MRI CONTRAST AGENTS FOR DIAGNOSIS AND PROGNOSIS OF TUMORS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2006-08-03 | — | — | WO | disclosed |
| EP-0967205-B1 | Labeling reactants and their use | WALLAC OY (FI) | 2003-09-17 | — | — | EP | disclosed |
| US-6080839-A | FOR LABELING OF A BIOSPECIFIC BINDING REACTANT USING SOLID-PHASE SYNTHESIS; LANTHANIDE CHELATES | WALLAC OY (FI) | 2000-06-27 | — | — | US | disclosed |
| EP-0967205-A1 | Labeling reactants and their use | WALLAC OY (FI) | 1999-12-29 | — | — | EP | disclosed |
| EP-0578067-A1 | Photochemical labeling of nucleic acids with europium-chelating reagents and their use in gene probe systems | BAYER AG (DE) | 1994-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305049-A1 | Mri Contrast Agents for Diagnosis and Prognosis of Tumors | TFRC, FOLR1, CD14 | NR1D1 1804/4885MTNR1A 1118/4885MTNR1B 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.